In summary, Tspyl2 gene therapy attenuates BLM-induced PF, partly by inhibiting the lung fibroblast-to-myofibroblast transition and TGF-β/Smad3 signaling pathway. This evidence concerns the gene TSPYL2 and pemphigus foliaceus.